Tocagen Receives European Medicines Agency Priority Medicines (PRIME) Designation for Toca 511 in High Grade Glioma

SAN DIEGO, July 24, 2017 -- (Healthcare Sales & Marketing Network) -- Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, today announced the European Medicines Agency (EMA) has granted Toca 511 (vocimagene amiretrorepvec... Biopharmaceuticals, Oncology, Regulatory Tocagen, Toca 511, glioma
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news